Clinical Guidelines

Trial-anchored psychedelic practice guidance

One index for manuals, protocols, and guidebooks linked to psychedelic clinical trials, now cross-checked against practitioner courses and provider pages. Everyone can browse the full index; Pro unlocks full competency depth.

Looking for something specific? Ask Blossom

Competency Explorer

One canonical map across trials, courses, and providers

Browse the shared skills taught across psychedelic clinical guidance and practitioner training, then compare what is common, protocol-specific, or only visible on course pages.

Competencies

663

Protocols

8

Matched

49

Filter map

Core competency map

Twelve competency categories. Tap a competency to inspect its linked sources inline.

  • Category page →
  • Category page →
  • Category page →
  • Category page →
  • Category page →
  • Category page →
  • Category page →
  • Category page →
  • Category page →
  • Category page →
  • Category page →
  • Category page →

Guideline Index

All clinical guidelines

144 entries grouped by protocol family.

  • trial protocol paperEvidence score: 90

    Acute Dose-Dependent Effects of Mescaline: Double-Blind Placebo-Controlled Study

    Attribution: Klaiber et al., 2024 (NCT04849013)

    Source guideline: Open link

    Preview competencies (3)

    • Pre-session screening and eligibility assessment

      Screen participants for psychiatric, medical, and substance-use factors that could increase risk or confound outcomes. Identify contraindications before administering psychedelic compounds.

    • Psychedelic session oversight

      Provide structured oversight of a prolonged psychedelic drug session in a controlled setting. Maintain continuous responsibility for participant welfare across the active and subacute phases of effects.

    • Physiological safety monitoring

      Continuously monitor key autonomic and physiological parameters that can change during psychedelic administration. Detect clinically meaningful deviations and respond appropriately.

    15 additional competency entries are available in the full framework.

    Unlock full competency framework

    Get complete cross-guideline skills, knowledge, safety, and ethics mappings.

    trial protocol paperEvidence score: 90

    Comparative Acute Effects of Mescaline, LSD and Psilocybin: Randomised Double-Blind Cross-Over Study

    Attribution: Ley et al., 2023 (NCT04227756)

    Source guideline: Open link

    Preview competencies (3)

    • Screening and contraindication recognition

      Identify participants who should not receive psychedelic compounds due to medical, psychiatric, or substance-use risk factors. Careful pre-session screening reduces the likelihood of adverse outcomes.

    • Physiological safety monitoring

      Measure and interpret cardiovascular and physiological responses during psychedelic administration. This includes tracking blood pressure, heart rate, body temperature, and pupil size to identify clinically relevant changes.

    • Psychedelic session monitoring

      Continuously supervise participants during the acute effect phase and maintain a calm, controlled setting for administration and observation. Monitor for changes in subjective state, autonomic effects, and emerging adverse events across the full session.

    13 additional competency entries are available in the full framework.

    Unlock full competency framework

    Get complete cross-guideline skills, knowledge, safety, and ethics mappings.

More from this library

The competency map feeds a set of standing tools: gap measurement, standards comparisons, a weekly change feed, and tailored exports.

Explore the underlying compound research

Each protocol family above maps to a compound profile with its papers, trials, and indication-level research summaries.